GB8900763D0 — Multi-dose syringe
Assigned to KABI VITRUM PEPTIDE HORMONES A · Expires 1989-03-08 · 37y expired
What this patent protects
A prefilled syringe comprising a phial (11) containing a measured quantity of an injectable product, a plunger (5) to expel the product out of the phial through a needle, and a two-part housing (1,2) for the phial and plunger in which the two parts are connected by interengaging …
USPTO Abstract
A prefilled syringe comprising a phial (11) containing a measured quantity of an injectable product, a plunger (5) to expel the product out of the phial through a needle, and a two-part housing (1,2) for the phial and plunger in which the two parts are connected by interengaging screw threads (3,4). A stop surface on one housing part cooperates with a corresponding surface (7) on the plunger to limit displacement of the plunger (5) into the phial (11), and the position relative to the phial of the stop surface can be varied by rotating the two housing parts (1,2) relative to one another. A graduated dosing ring (19) is mounted coaxial with, adjacent to, and rotatable relative to both housing parts (1,2).
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.